The healthcare investment world is just over 90 days out from the annual San Francisco conference week, and investors are already inking their plans for a busy week. Within that hectic JPM ecosystem, RESI SF is a key venue to meet with early stage startups, and many investors are already made their plans to attend.
LSN would like to make our first RESI San Francisco panel announcement: Healthcare IT Investors. This panel focuses on investors that are looking for innovative startups using software to solve healthcare problems, from drug discovery and development to care provision and management. Significant investment is pouring into this sector, with an estimated $4.5 billion invested in 2015. At RESI, we’ll hear from 5 highly active investors from a diverse variety of firms on what they’re looking for in healthcare IT at present, and how an opportunity can catch their attention.
Join us at RESI to hear from these experienced investors discuss how they search for and assess healthcare IT opportunities, and what areas of this diverse sector are most attractive at present.
Biotech and medtech industry executives are already drawing up their itineraries for January’s healthcare conference week in San Francisco. It’s on track to be a busy week for us all. Among the many events and receptions taking place, the Redefining Early Stage Investments Conference (RESI SF) stands alone in providing a targeted opportunity for early stage biotech and medtech companies to schedule up to 16 face-to-face investor meetings in one venue, with the potential for many more ad-hoc investor discussions throughout the day.
Partnering is RESI’s core, but at RESI SF also provides a full day of investor panels and workshops devoted to early stage life science investment topics. We’ll see the return of the RESI Asia-North America track, with content for entrepreneurs who are looking to the Asia Pacific region as a source of investment or future customers. RESI will also feature sessions focused on investors in each main life science technology vertical, and on key investor categories including Family Offices, Angels and Big Pharma, and a new session on Tech Giants in Healthcare.
With a full day of content and meetings, we’re on course for another sellout San Francisco RESI event. Don’t leave it too late to get your ticket.
After the huge success of RESI Boston, which attracted over 700 attendees for an unprecedented number of face to face meetings, it’s time to look ahead to this winter’s conference season. RESI will be joining the JPM fray for our largest event yet. The 11th Redefining Early Stage Investments (RESI) Conference will take place on January 10th in San Francisco.
2016 has seen a grand RESI tour, beginning with a sellout event in San Francisco, then to Houston, and up to Toronto for our first international RESI event, and home to Boston in the fall. For 2017 we’ll once again open the year with a splash in San Francisco. With other events focusing on late stage or publicly traded companies, RESI San Francisco will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. As RESI SF is highly likely to hit capacity again, we encourage you to register early.
RESI is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.
With LSN’s Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees.
The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, we’ve reached capacity at our venue. We’re therefore unable to take any more registrations.
However, here’s the program guide; we hope that if you didn’t make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If you’d like to attend a future RESI event, plan early!
Life Science Nation’s mission of connecting scientist entrepreneurs with capital gave rise to the Redefining Early Stage Investments (RESI) conference nearly 3 years ago. As we approach our seventh RESI conference, during the highly anticipated JP Morgan week in San Francisco, we’re expecting a record of well over 300 investors representing over 200 different firms in attendance. Figure 1 shows a breakdown of investors by type who will be at RESI San Francisco on January 12, 2016. You can also view the firms represented here.
Venture capital is the most represented investor type, and this includes a growing number of non-traditional venture firms in today’s investment landscape. For instance, the relatively new emergence of the “micro VC” has more capital flowing into seed and series A stage companies. As shown here, several other investor classes looking for early-stage life science technologies that don’t fall under the venture capital umbrella also have a large presence at the RESI conference. This diversity of investors means that RESI Partnering can provide RESI’s great variety of attendees with the opportunity to make a connection with a financing partner that’s the right fit for their round.
Life Science Nation’s network of varied investor types will be showcased on an assortment of panels throughout the day. The 16 panels scheduled to take place at RESI San Francisco will cover the full range of companies in the life science space (biotech, medtech, diagnostic and health IT) and the different investor class’ tactical guidance for navigating the investment process of their respective niches and outlook on the future of each sector. The LSN research team’s unique perspective on the investment landscape has spurred a new panel that will be held for the first time at RESI San Francisco, Consumer Health “Investing in Innovative Products for Healthy Living,” and the return of two panels from former RESI events, Asia-Pacific Investors, “Forging Cross-Border Collaborations in Healthcare,” and Orphan & Rare Disease Investors, “Seeking Returns On Investing In Small Patient Populations”.
The fundraising process is typically a lengthy one, therefore multiple interactions with prospective investors and strategic partners are essential to a successful campaign. The RESI conference is an ongoing series that provides just that, allowing entrepreneurs to interface with a diverse field of investors, foster existing relationships and make new connections throughout the year, at multiple events. RESI San Francisco is just the first stop for 2016, with additional RESI conferences being held in Houston, Toronto and Boston, later in the year.
This ongoing chain of conferences coupled with the forward-looking investor mandate information used in our partnering platform really makes RESI stand out in terms of the ability to make meaningful connections. To see a demonstration of just how effective the partnering system can be at finding a match, please watch this video.
One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.
At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company’s evaluation process, and what can you do to position your startup to make a deal? Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.
Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 